Varila, Taru
Åbo Akademi University · University of Turku
3 papers on CoChatORCID 0000-0002-5637-7507
Most cited papers
- Verified
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 149
- Verified
Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 65
- Verified
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias
Mäkelä, E., Pavic, K., Varila, T., Salmenniemi, U., Löyttyniemi, E., Nagelli, S. G., Ammunét, T., Kähäri, V.-M., Clark, R. E., Elo, L. L., et al. (2021) · Clinical Cancer Research
Chronic Myeloid Leukemia TreatmentsRNA Research and Splicing
Cited by 18
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free